US 12,358,903 B2
FXR (NR1H4) modulating compounds
Peter A. Blomgren, Issaquah, WA (US); Kevin S. Currie, North Bend, WA (US); Julie Farand, San Mateo, CA (US); Christian Gege, Mauer (DE); Jeffrey E. Kropf, Issaquah, WA (US); and Jianjun Xu, Bellevue, WA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Jan. 11, 2022, as Appl. No. 17/573,534.
Application 17/573,534 is a division of application No. 16/409,184, filed on May 10, 2019, granted, now 11,247,986.
Application 16/409,184 is a division of application No. 15/619,675, filed on Jun. 12, 2017, granted, now 10,329,286, issued on Jun. 25, 2019.
Claims priority of provisional application 62/349,479, filed on Jun. 13, 2016.
Prior Publication US 2022/0242858 A1, Aug. 4, 2022
Int. Cl. C07D 413/14 (2006.01); C07D 401/14 (2006.01)
CPC C07D 413/14 (2013.01) [C07D 401/14 (2013.01)] 7 Claims
 
1. A compound according to Formula (I):

OG Complex Work Unit Chemistry
wherein:
Q is phenylene optionally substituted with one or two substituents selected from halogen, methyl, —CH2F, —CHF2, and —CF3;
Z is:

OG Complex Work Unit Chemistry
L is a bond;
X is N;
R1 is C1-4-alkyl or C3-6-cycloalkyl;
R3 is halogen, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkoxy, or halo-C1-4-alkoxy;
R4 is hydroxyl, C1-6-alkoxy, halo-C1-6-alkoxy, or —NR5R6;
R5 is hydrogen, C1-6-alkyl, or halo-C1-6-alkyl;
R6 is hydrogen or C1-6-alkyl, wherein said C1-6-alkyl is optionally substituted with 1 to 6 substituents independently selected from halogen, —SO3H, and —CO2H;
R7 and R8 are independently selected from halogen, C1-3-alkoxy, and fluoro-C1-3-alkoxy; and
n is 0 or 1;
or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.